You are here: Home: CACU 1 | 2008: Faculty Disclosures

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice reported real or apparent conflicts of interest for themselves (or their spouses/partners), which have been resolved through a conflict of interest resolution process: Aviva Asnis-Alibozek, PA-C, MPAS — Salary: AstraZeneca Pharmaceuticals LP; Shareholder of: AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — Shareholder of: Amgen Inc and Genentech BioOncology. All other Research To Practice staff and external reviewers: No real or apparent conflicts of interest to report.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr GregoryConsulting Fees: Genentech BioOncology; Contracted Research: Genentech BioOncology, GlaxoSmithKline; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals Inc. Dr RichardsonSpeakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc.


This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

 

Editor
Neil Love, MD

Publications discussed by
Stephanie A Gregory, MD
Paul G Richardson, MD
Additional Select Publications

Editor's Office

Subscriptions

Media Center
Download PDF
Audio Files
Podcast
Previous Issues

 

Terms and Conditions of Use and General Disclaimer | Privacy Policy
Copyright © 2008 Research To Practice. All Rights Reserved.